Ameritas Advisory Services LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 75,983 shares of the biopharmaceutical company’s stock after buying an additional 2,633 shares during the quarter. Ameritas Advisory Services LLC’s holdings in Pfizer were worth $2,016,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the business. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP boosted its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in shares of Pfizer during the second quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Pfizer in the third quarter valued at about $35,000. Finally, Joseph Group Capital Management lifted its stake in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares during the period. Institutional investors own 68.36% of the company’s stock.
Insider Activity at Pfizer
In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Get Our Latest Analysis on Pfizer
Pfizer Stock Performance
Shares of NYSE PFE opened at $26.30 on Tuesday. The stock has a market capitalization of $149.06 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a 50 day moving average price of $26.08 and a 200 day moving average price of $27.99. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the business earned ($0.17) earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.
Pfizer Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 227.03%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
- Five stocks we like better than Pfizer
- What Are Growth Stocks and Investing in Them
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Stock Dividend Cuts Happen Are You Ready?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- CD Calculator: Certificate of Deposit Calculator
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.